John Oyler, BeiGene CEO (Paul Yeung/Bloomberg via Getty Images)

Bris­tol My­ers wants to pull out of its Abrax­ane deal in Chi­na. BeiGene says no way

A year and a half af­ter Chi­nese of­fi­cials or­dered BeiGene to stop sell­ing Bris­tol My­ers Squibb’s Abrax­ane in the wake of an alarm­ing in­spec­tion of a US fa­cil­i­ty, the man­u­fac­tur­ing is­sues at the root of the im­port sus­pen­sion still ap­pear un­re­solved.

And Bris­tol My­ers wants to axe the Abrax­ane sup­ply deal al­to­geth­er.

But BeiGene, which is cur­rent­ly in ar­bi­tra­tion pro­ceed­ings against its Big Phar­ma part­ner, won’t let it off the hook so eas­i­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.